Biotechnology stocks show volatility as BioNTech falls and BB Biotech hits high

The biotechnology sector is experiencing significant movement, highlighted by contrasting performances from BioNTech and BB Biotech.

BioNTech shares experienced high volatility, dropping 8.37 percent to a closing price of 102.08 USD following negative Phase 2 data from an oncology program. This decline followed a period of gains driven by positive news related to Moderna. Despite the drop, technical indicators suggest support levels remain around the 97 to 99 USD range.

In contrast, BB Biotech reached a 52-week high of 60.90 EUR, driven by a broader recovery in the biotech segment and strong financial results. The company reported a net profit of 451 million CHF for the second quarter of 2026, a significant turnaround from a 100 million CHF loss in the previous year. The Bellevue Group, the parent company, also noted increased profits, citing BB Biotech as a primary driver. Despite the rally, Morningstar estimates the stock still trades at a discount to its Net Asset Value of 61.85 CHF.